Top Story

SLE linked with increased atherosclerotic risk in early disease stages

November 17, 2017

According to findings, systemic lupus erythematosus appears to increase atherosclerotic risk in its early phase, while traditional risk factors have a greater impact on atherosclerosis during the later stages of SLE.
and 138 healthy controls who were enrolled in the Toronto Risk Factor Study. The Toronto Risk Factor Study began in 1998 and enrolled 250 women with SLE and 250 age-matched, healthy female controls from a family practice clinic. The present study analyzed the initial cohort 15 years later for the incidence of atherosclerotic cardiovascular (CV) events. The following were classified as CV events: angina pectoris; myocardial infarction (MI; fatal or nonfatal); transient ischemic attack (TIA); and stroke (fatal and nonfatal).

In the 210 patients with SLE and 138 control patients for whom 15-year follow-up data were available, 19.5% of patients with SLE and 6.5% of controls experienced atherosclerotic CV events. Some patients had more than one CV event. Four control group patients had both angina and MI, while one patient with SLE experienced both MI and stroke. In the SLE group, the incidence of CV events was 0.015 events/patient-years, and among controls, the incidence of CV events was 0.004 events/patient years. Patients with SLE had a higher prevalence of coronary artery disease (CAD) vs. controls (15.2% vs. 3.6%). Conversely, there was no statistically significant difference between SLE and control patients for CVD (TIA and stroke: 4.8% vs. 2.2%). Patients with SLE had a mean time to the occurrence of CV events of 8.8 years. There was a statistical difference in the likelihood of CV event development in patients with SLE vs. controls. In an analysis using Kaplan-Meier survival curve, the researchers found patients with SLE consistently had higher rates of CV events, and this disparity increased with longer follow-up.

In the JournalsPerspective

Discontinuation of postmenopausal hormone therapy elevates cardiac, stroke death risk

November 16, 2017
In the first year after discontinuation of postmenopausal hormone therapy, the risk for cardiac and stroke death increases, particularly among women aged younger than 60…
FDA News

FDA to examine heart-related deaths associated with febuxostat

November 16, 2017
The FDA announced that preliminary data from a safety trial demonstrate that, compared with allopurinol, febuxostat is linked to an increased risk for heart-related…
In the Journals Plus

DCCT: Intensive control may blunt only short-term CV effects of weight gain in type 1 diabetes

November 16, 2017
Adults with type 1 diabetes who gained excessive weight during a 6-year, intensive glycemic management regimen experienced a cardiovascular event rate over 13 years…
More Headlines »